How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Etentamig (drug), Carfilzomib (drug), Pomalidomide (drug), Elotuzumab (drug)
How long the study runs: Study runs about 43 months (dates as stated)
About the drug or intervention: Etentamig — drug: Intravenous (IV) Infusion · Carfilzomib — drug: IV Infusion · Pomalidomide — drug: Oral Capsule · Elotuzumab — drug: IV Infusion · Selinexor — drug: Oral Tablet · Bortezomib — drug: Subcutaneous or IV Injection · Dexamethasone — drug: Oral Tablet or IV Infusion
Patient visit burden: Not specified by the sponsor

In plain English

This study tests a drug called etentamig, given through a drip into a vein (intravenous), on its own in adults whose multiple myeloma has come back or stopped responding to treatment (relapsed or refractory). It compares etentamig with standard treatments chosen by the doctor. The study is funded by AbbVie.

Who can take part

Adults with relapsed or refractory multiple myeloma diagnosed during or after their last treatment, as set out in the study plan.
Fairly well day-to-day: an Eastern Cooperative Oncology Group (ECOG) score of 2 or less (a scale of how well you can carry out daily activities).
Measurable disease shown by tests within 28 days of joining — for example, a certain level of abnormal protein in the blood or urine, or abnormal free light chains (a type of protein) in the blood.
Have already had at least 2 lines of myeloma treatment, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (three common types of myeloma medicine). People joining in the US or Puerto Rico only need at least 1 previous line, as long as it included those three types.
Able to safely receive a standard available therapy chosen by the doctor, based on the medicine's approved information, past treatment, and hospital guidelines.

Who may not be able to

Drug or alcohol misuse in the last 6 months that the doctor considers significant.
Other significant health conditions in the last 6 months (for example affecting the nerves, mind, hormones, metabolism, immune system, heart, lungs, or liver) that would affect taking part, in the doctor's view.
Myeloma that has spread to the brain or spinal cord (central nervous system).
Previous treatment targeting BCMA (B-cell maturation antigen, a protein on myeloma cells).

What taking part involves

• Etentamig given alone through a drip into a vein, or
• A standard available therapy for multiple myeloma chosen by your doctor.

Time commitment: Not stated — ask the trial team about how many visits are needed, how long the study lasts, and what tests or procedures taking part would involve.

Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 421
Started: 2024-05-19
Last checked: 2026-08

Plain English Summary

What is this study?

• Testing a new treatment for multiple myeloma
• Phase3 - 421 participants
• Multiple myeloma (MM) is a cancer of the blood's plasma cells

Who can take part?

• Ages 18 Years and over
• Diagnosed with multiple myeloma

Where?

• Cambridge - Addenbrookes Hospital /ID# 261104
• Edinburgh - Western General Hospital /ID# 261106
• London - Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 262488
• Nottingham - Nottingham City Hospital /ID# 261105
• +3 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world. In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Multiple Myeloma

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

Biomarkers mentioned

CD38

Treatment history

Treatments you must have had:

✓ measurable disease with at least 1 of the following assessed within 28 days of enrollment:

What the study is looking for

✓activity scale (ECOG) performance of \<= 2.
✓Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as...
✓Must have cancer that can be measured on scans with at least 1 of the following assessed within 28 days of enrollment:
✓Serum M-protein \>= 0.5 g/dL (\>= 5 g/L).
✓Urine M-protein \>= 200 mg/24 hours.

Who cannot take part

✗Clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months.
✗Central nervous system involvement of MM.
✗Has received B-cell maturation antigen (BCMA)-treatment that targets specific changes in the cancer.

See the full criteria

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance of \<= 2. * Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol. * Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment: * Serum M-protein \>= 0.5 g/dL (\>= 5 g/L). * Urine M-protein \>= 200 mg/24 hours. * In participants without measurable serum or urine M protein, serum free light chain (FLC) \>= 100 mg/L (10 mg/dL) (involved light chain)and an abnormal serum kappa lambda ratio. * Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb). \-- US and Puerto Rico only: Participant must have received at least 1 or more line of therapy, including exposure to a PI, an IMiD, and an anti-CD38 mAb. * Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines. Exclusion Criteria: * Clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months. * Clinically significant conditions such as but not limited to the following: neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that would adversely affect the participant's participation in the study. * Central nervous system involvement of MM. * Has received B-cell maturation antigen (BCMA)-targeted therapy.